KK2223
Phase 1Recruiting 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
T-cell NHL (PTCL or CTCL)
Conditions
T-cell NHL (PTCL or CTCL)
Trial Timeline
Jan 23, 2026 → Sep 1, 2030
NCT ID
NCT07192471About KK2223
KK2223 is a phase 1 stage product being developed by Kyowa Kirin for T-cell NHL (PTCL or CTCL). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07192471. Target conditions include T-cell NHL (PTCL or CTCL).
What happened to similar drugs?
5 of 10 similar drugs in T-cell NHL (PTCL or CTCL) were approved
Approved (5) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07192471 | Phase 1 | Recruiting |
Competing Products
20 competing products in T-cell NHL (PTCL or CTCL)